in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Ranbaxy’s Controversial India Plant Gets Australian, U.K. Regulatory Approvals
2:13 AM MDT | March 23, 2009 | Deepti Ramesh
Ranbaxy Laboratories (Gurgaon, India) says that the Medicines and Healthcare products Regulatory Agency (MHRA; London) of the U.K., and the Therapeutic Goods Administration (TGA; Canberra), Australia’s drug regulatory body, have issued good manufacturing practice (GMP) certificates for Ranbaxy’s Paonta Sahib, India manufacturing facility, following a joint audit conducted last October. Ranbaxy says that the MHRA approval will cover product filings for the U.K. and also apply to product filings for the entire European Union. The U.S. FDA said last...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee